ArQule (ARQL) Receives Milestone Payment from Wyeth (WYE)
More News related to ARQL
- ArQule, Inc. to Present at 8th Annual Needham Life Sciences Conference on June 10, 2009
- ASCO Presentations Highlight Findings from Clinical Trials with ArQule's (ARQL) c-MET Inhibitor, ARQ 197
- ASCO Presentations Highlight Findings from Clinical Trials with ArQule's c-MET Inhibitor, ARQ 197
- CORRECTING and REPLACING ArQule, Inc. to Present at Leerink Swann Cancer Roundtable on May 20, 2009
- ArQule, Inc. to Present at Leerink Swann Cancer Roundtable on May 20, 2009
More News related to WYE
- Wyeth Pharmaceuticals and Catalyst Biosciences Announce Agreement to Develop and Commercialize Factor VIIa Products
- Wyeth (WYE) Extends Collaboration Agreement With Trubion Pharmaceuticals (TRBN)
- Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
- Wyeth Files Definitive Proxy Statement and Announces Date for Annual Meeting of Stockholders
- New Therapies, Including Novel Biologic Agents from Elan/Wyeth and Eli Lilly, Will Drive Robust 11 Percent Annual Growth In the Alzheimer's Disease Market
More News related to Corporate News
- Sanofi-aventis (SNY) Reports Results of Long-Term, 5-Yr Study of Lantus(R) vs. NPH Insulin
- CombinatoRx (CRXX) Publishes Research Demonstrating Improved Selectivity Through Synergistic Combinations
- Wells Fargo (WFC)and Wachovia Capital Markets Businesses Branded as Wells Fargo Securities
- Duke Energy (DUK) to Build New Wind Energy Project in Eastern Colorado
- Spectrum Pharmac (SPPI) Receives Complete Response Letter from FDA for Zevalin
ArQule, Inc. (NASDAQ: ARQL) announced the receipt of a milestone payment from Wyeth (NYSE: WYE) in connection with the filing of an Investigational New Drug (IND) application by Wyeth to the U.S. Food and Drug Administration (FDA) related to a compound under development for Alzheimer's disease.
In connection with its former chemistry services business, ArQule has agreements with pharmaceutical collaborators such as Wyeth. Certain of the agreements include provisions for milestone and royalty payments in the event of development and commercialization of drugs derived from compounds provided to them by ArQule. [SM]
Related Categories
Corporate NewsStocks Mentioned
-0.15Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
